Biopharmaceutical company Journey Colab who are working to unlock the science of psychedelics and build a new model for addiction treatment recently announced that Joel A. Posener, MD would be joining the company in the role of Chief Medical Officer.
An experienced leader in neuroscience drug development, Dr. Posener joins the Journey Colab team as the company advances psychedelic therapeutic approach for Alcohol Use Disorder. Journey Colab is utilizing synthetic Mescaline HCl (JOUR-5700) to develop a therapeutic for Alcohol Use Disorder (AUD).
Dr. Joel Posener is a board-certified psychiatrist who received his MD from McGill University and completed his residency and research fellowship at the Massachusetts Mental Health Center and Harvard Medical School. Dr. Posener comes to Journey Colab from Neumora Therapeutics where he previously served as Vice President of Clinical Research.
About Journey Colab
Journey Colab is using psychedelic science to develop a new addiction treatment model that combines neuroplasticity-promoting drugs with psychotherapy and community support.
The firm’s lead compound is synthetic Mescaline HCl for individuals with alcohol use disorder (AUD), who are in severe need of a consistent and long-lasting cure.
Journey Colab, through a unique stakeholder structure, has developed an experienced team committed to the goal of developing scientifically thorough and clinically validated therapies as well as expanding equitable access to health care.
The goal of Journey Colab’s leading team of drug development experts and scientific advisors is to develop an integrated treatment strategy that incorporates new medicines with psychosocial therapy and community support.
Synthetic Mescaline HCl, Journey’s lead compound in development, has distinct advantages over other psychedelics and may be particularly well suited to the treatment of AUD. The business plans to utilize the exciting science of psychedelics to provide long-lasting recovery for people addicted to drugs.
About Dr. Joel Poesner – Journey Colab Chief Medical Officer
Dr. Posener began his career as an academic instructor, first at Harvard and its affiliated facilities and then at Washington University in St. Louis, before joining the pharmaceutical sector in 2004 after completing his educational training.
Over the course of his 18 year career, Dr. Posener has held progressively senior posts in neuroscience research, including both psychiatry and neurology, at AstraZeneca, Pfizer, and Takeda. In his previous role at Neumora, he was responsible for clinical development of the programs within the discovery portfolio.
Dr. Posener has spent his career in academe and currently serves as Clinical Professor of Psychiatry at Temple University concurrent with his professional exploits.
Dr. Posener cited a prevalence of 28 million cases of Alcohol Use Disorder over the past year noting that Journey Colab’s model has the potential to help an extraordinary number of people. Noting he was”thrilled to join the team as we advance into clinical development.”
He expanded stating and existing treatments provide very limited benefit while sychedelics represent an exciting new therapeutic approach.
